Karol Osipowicz, Ph.D.’s Post

1. Scientists at the University of Pittsburgh have validated a new blood test platform for measuring over a hundred Alzheimer's disease biomarkers. 2. The platform aims to enhance early diagnostics by capturing the complex nature of Alzheimer's pathology. 3. Early detection of pathological changes is crucial for improving the effectiveness of new treatments and slowing disease progression. 4. Current Alzheimer's diagnostic methods are resource-intensive and burdensome for patients. 5. The proof-of-concept study involved blood samples from 113 cognitively normal older adults in Southwestern Pennsylvania. 6. The NULISAseq CNS Disease 120 Panel measures classical and additional biomarkers related to neurodegenerative diseases. 7. The platform's performance was validated against classical Alzheimer's assays and correlated with amyloid imaging measures over two years. 8. Researchers aim to develop a predictive model to assess biomarker changes and their relationship to disease progression and treatment decisions.

I am pleased to have been part of a significant milestone towards a more accessible Alzheimer’s diagnosis as a co-author on CEOi - Global CEO Initiative on Alzheimer's Disease BBM Workgroup’s inaugural manuscript, titled "The Global CEO Initiative on Alzheimer’s Disease performance recommendations for blood-based biomarker tests," published in Nature Reviews Neurology.   Alzheimer’s blood tests have the potential to revolutionize early and accurate diagnoses for patients with cognitive impairment. However, the performance of these tests can vary, raising the question of the minimum accuracy required for a test to be clinically useful.   To address this, CEOi convened a diverse group of expert stakeholders, marking the first expert consensus on a unified framework for BBM tests in clinical practice.   While amyloid PET and CSF biomarkers have played a critical role, their high cost and limited accessibility have hindered widespread adoption. With new treatments emerging, the need for accessible diagnostic methods like BBM tests is more urgent than ever.   GAP is proud to be part of the solution and will continue as we launch our Bio-Hermes-002 study. Discover more about the newly published recommendations and join us in advancing Alzheimer's diagnostics for all! https://lnkd.in/eGCEFSCZ

#RecentlyPublished Read now ➡️ "A Combination of Heavy Metals and Intracellular Pathway Modulators Induces Alzheimer Disease-like Pathologies in Organotypic Brain Slices" by Dhwani S. Korde and Christian Humpel. We developed an ex vivo brain slice model to model amyloid-beta plaque and tau neurofibrillary tangle-like pathologies. We found that heavy metals and pathway modulators impact the formation of these pathologies. This model has potential applications for screening drugs or therapies in the future. The article 👉 https://lnkd.in/dQe73siJ #alzheimer #tau

"Early diagnosis of Alzheimer's disease is crucial for optimizing therapy and preventing irreversible brain damage," said a group of scientists from Bar-Ilan University. In a recent study, they described a liposome-based method to detect and possibly treat the disease at an early stage. --> The results showed physiological improvements in a C. elegans Alzheimer's model 🐛 --> They also found fluorescence-marked liposomes in the brain of a mouse Alzheimer's model before beta-amyloid plaque formation 🐭 The authors concluded that “This innovative strategy holds potential as a breakthrough in the battle against Alzheimer’s disease, offering a ray of hope for early detection and targeted therapy.” 💊💉 For more details, you can read the news article I wrote. (or the original publication that I leave in the comments) https://lnkd.in/du4cKqTw #alzheimer #liposomes #amyloid

I'm delighted to announce the publication of our latest opinion article titled “Photobiomodulation Therapy: A Novel Therapeutic Approach to Alzheimer’s Disease Made Possible by the Evidence of a Brain–Gut Interconnection.” This article delves into the promising potential of #Photobiomodulation (PBM) therapy as a non-invasive treatment for #Alzheimers disease (AD). The study explores the intricate #brain–gut connections that could play a pivotal role in AD, highlighting how #gut #microbiota and bacterial translocation would contribute to peripheral inflammation, immune modulation, and ultimately, the cognitive deficits associated with the disease. Our research suggests that PBM, known for stimulating mitochondrial activity and enhancing adenosine triphosphate synthesis, could be a game-changer in AD treatment. By applying PBM directly to the head and abdomen, we propose a dual approach that targets the complex components of AD, offering a beacon of hope for those affected by this challenging condition. https://lnkd.in/dRD34xUV Many thanks to Francois Roman, Benjamin Lelouvier, Céline Ribière and Prof. Jacques Touchon. Journal of Integrative Neuroscience, Vaiomer, REGEnLIFE

Excellent research by Guillaume Blivet the team at REGEnLIFE: "Photobiomodulation Therapy: A Novel Therapeutic Approach to Alzheimer’s Disease Made Possible by the Evidence of a Brain–Gut Interconnection" Recent treatments only slow AD progression with significant adverse effects. Gut microbiota’s role in AD pathogenesis is becoming clearer, affecting neurophysiological responses via the brain-gut axis: PBM uses red or near-infrared light to activate mitochondrial function, enhancing energy production and reducing oxidative stress. Applied both transcranially and abdominally, it offers a novel, non-invasive method to influence both brain and gut health. Research Findings and Clinical Implications Studies show altered gut microbiota in AD patients could be linked to the disease's inflammatory processes. #PBM has shown potential in modifying #gut #microbiota, improving #mitochondrial function, and reducing #inflammation, thereby potentially ameliorating AD symptoms. It suggests a multitarget therapeutic approach, targeting both CNS symptoms and gut health simultaneously. I have been hugely inspired by the work of this team, similar to the discussed PBM applications, the CeraThrive System utilises red and NIR technology to influence both #brain and gut health, not only for #neurodegeneration, but other long term health issues. https://lnkd.in/ekxkatWA

Background: Parkinson disease (PD) is a prevalent neurodegenerative disorder affecting dopaminergic neurons in the substantia nigra (SN). Neuroinflammation has a vital role in PD pathophysiology. Objectives: This study assesses whether the neuroinflammatory molecular and signaling pathways could be associated with PD’s progression and clinical manifestations. Materials & Methods: PubMed, Web of Science, Embase, and Scopus databases were investigated from 2006 until December 2023 to find relevant studies. All observational studies written in English and reporting qualitative or quantitative information on the relationship between neuroinflammation and PD were included in this review. Results: Finally, 41 papers were involved in the systematic review. According to the involved studies, it is suggested that tumor necrosis factor-α, C-reactive protein, microsomal prostaglandin E synthase1, toll-like receptor-4 (TLR-4), CCL23, CCL25, TNF-receptor superfamily member 9, EV-derived cytokines, transforming growth factor alpha, vascular endothelial growth factor A, SH-SY5Y, TLR 2/4, miR-485-3p, leucine-rich repeat kinase 2, and α-synuclein may be upregulated in the PD patients. Also, the activity of astrocytes and microglial cells was reported to be increased in PD patients through different mechanisms.  Conclusion: This study demonstrated that the neurodegeneration in PD could be initiated by α-synuclein protein aggregation and the activation of astrocytes and microglial cells, which leads to neuroinflammation characterized by inflammatory responses in neurons. Finally, chronic neuroinflammation could be the cause of dopaminergic neuronal death in SN. The impact of both single and all factors involved in neuroinflammation was assessed to plan further studies in a particular pathway to intercept the onset of inflammatory pathways in favor of therapeutic purposes.    #CReactiveProtein #TumorNecrosisFactorα, #αSynuclein, #TollLikeReceptor2, #TLR9

Excellent research by Guillaume Blivet the team at REGEnLIFE: "Photobiomodulation Therapy: A Novel Therapeutic Approach to Alzheimer’s Disease Made Possible by the Evidence of a Brain–Gut Interconnection" Recent treatments only slow AD progression with significant adverse effects. Gut microbiota’s role in AD pathogenesis is becoming clearer, affecting neurophysiological responses via the #braingutaxis: PBM uses red or near-infrared light to activate mitochondrial function, enhancing energy production and reducing oxidative stress. Applied both transcranially and abdominally, it offers a novel, non-invasive method to influence both brain and gut health. Research Findings and Clinical Implications Studies show altered gut microbiota in AD patients could be linked to the disease's inflammatory processes. #PBM has shown potential in modifying #gut #microbiota, improving #mitochondrial function, and reducing #inflammation, thereby potentially ameliorating AD symptoms. It suggests a multitarget therapeutic approach, targeting both CNS symptoms and gut health simultaneously. I have been hugely inspired by the work of this team, similar to the discussed PBM applications, the CeraThrive System utilises red and NIR technology to influence both #brain and gut health, not only for #neurodegeneration, but other long term health issues. https://lnkd.in/ekxkatWA

We are thrilled to share that ALZpath Inc. has signed a licensing agreement with Beckman Coulter Diagnostics to leverage our proprietary #pTau217 antibody for the development of a blood-based diagnostic test for #Alzheimer's disease. This innovative test will be run on Beckman Coulter’s state-of-the-art DxI 9000 Immunoassay Analyzer, aiming to transform Alzheimer's diagnosis globally. The ALZpath pTau217 antibody is renowned for its high performance, and integrating our antibody into a blood-based in vitro diagnostic (IVD) test on Beckman Coulter’s DxI 9000 platform, known for its precision and scalability, will significantly enhance access to early and accurate testing for Alzheimer’s disease pathology. Chad Holland, ALZpath CEO, stated, “Collaborating with Beckman Coulter will significantly expand access to precise testing and early diagnosis for patients around the world.” Kathleen Orland from Beckman Coulter added, “We are excited about the combination of ALZpath and Beckman Coulter innovations coming together to develop a new fully automated, high throughput, blood-based Alzheimer's disease test.” Stay tuned for more updates as we work together to revolutionize Alzheimer’s diagnostics! 📌 Read the full press release here: https://lnkd.in/gbvC4p4B 📌 Learn more about ALZpath here: https://alzpath.bio/ #AlzheimersDiagnosis #pTau217 #InnovativeDiagnostics #BloodTest #DxI9000 #HealthcareInnovation #EarlyDetection #Neurology #Biotech #MedicalBreakthrough #PatientCare #ClinicalResearch #PrecisionMedicine #GlobalHealth #FutureOfMedicine

#neurodegenerativedisorders #Tau #synapses #cells #therapy Therapies for Tau-associated neurodegenerative disorders: targeting molecules, synapses, and cells https://lnkd.in/g-KWE4q3 University of Cambridge Advances in experimental and computational technologies continue to grow rapidly to provide novel avenues for the treatment of neurodegenerative disorders. Despite this, there remain only a handful of drugs that have shown success in late-stage clinical trials for Tau-associated neurodegenerative disorders. The most commonly prescribed treatments are symptomatic treatments such as cholinesterase inhibitors and N-methyl-D-aspartate receptor blockers that were approved for use in Alzheimer’s disease. This mini-review will highlight five key avenues of academic and industrial research for identifying therapeutic strategies to treat Tau-associated neurodegenerative disorders. These avenues include investigating (1) the broad class of chemicals termed “small molecules”; (2) adaptive immunity through both passive and active antibody treatments; (3) innate immunity with an emphasis on microglial modulation; (4) synaptic compartments with the view that Tau-associated neurodegenerative disorders are synaptopathies. Although this mini-review will focus on Alzheimer’s disease due to its prevalence, it will also argue the need to target other tauopathies, as through understanding Alzheimer’s disease as a Tau-associated neurodegenerative disorder, we may be able to generalize treatment options. For this reason, added detail linking back specifically to Tau protein as a direct therapeutic target will be added to each topic.